Consensus Celldex Therapeutics, Inc. London S.E.

Stocks

0HUU

US15117B2025

Biotechnology & Medical Research

Delayed London S.E.			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

08-07	Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q2 Revenue $0.0M	MT
08-07	Celldex Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Evolution of the Average Target: Celldex Therapeutics, Inc.

Evolution of the Target Price: Celldex Therapeutics, Inc.

Changes in Analyst Recommendations: Celldex Therapeutics, Inc.

00368e80a4.ad5li1CvvTE43jMhE0jomjriRxbhzZWLen0VgkRv6g8.Bbwi4jXq7Gh_7VRPVDK-qQuDPye0mdi7Hzp-2y06nTgNpAbuNevrS3G_XA~36a2f519017ae58a1f8b8d30c25efdef

Analysts' recommendations: Celldex Therapeutics, Inc.

07-22	Celldex's Phase 3 Barzolvolimab Study in Chronic Spontaneous Urticaria in Focus After Prurigo Nodularis Exit, Morgan Stanley Says	MT
07-22	Morgan Stanley Adjusts PT on Celldex Therapeutics to $40 From $44, Maintains Overweight Rating	MT
06-10	UBS Adjusts Price Target on Celldex Therapeutics to $45 From $38, Maintains Buy Rating	MT
04-20	Barclays Upgrades Celldex Therapeutics to Overweight From Underweight, Adjusts Price Target to $45 From $24	MT
03-23	Celldex Therapeutics Shares Rise After Wolfe Research Upgrade	MT
03-23	Wolfe Research Upgrades Celldex Therapeutics to Outperform From Peer Perform, PT is $44	MT
02-26	Morgan Stanley Lifts Price Target on Celldex Therapeutics to $44 From $43, Keeps Overweight Rating	MT
11-06	Celldex Presents Additional Positive Data Demonstrating Barzolvolimab's Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria Study	CI
21/10/25	Mizuho Initiates Celldex Therapeutics at Outperform With $48 Price Target	MT
13/10/25	Barclays Initiates Celldex Therapeutics at Underweight With $25 Price Target	MT
09/05/25	UBS Adjusts Price Target on Celldex Therapeutics to $38 From $44, Maintains Buy Rating	MT
28/04/25	Canaccord Genuity Initiates Coverage on Celldex Therapeutics With Buy Rating, $64 Price Target	MT
20/03/25	Morgan Stanley Initiates Celldex Therapeutics at Overweight With $46 Price Target	MT
07/10/24	Citigroup Initiates Celldex Therapeutics at Buy With $70 Price Target	MT
30/09/24	Goldman Sachs Initiates Coverage on Celldex Therapeutics With Neutral Rating, $45 Price Target	MT
27/09/24	Wolfe Research Downgrades Celldex Therapeutics to Peer Perform From Outperform	MT
26/09/24	Wells Fargo Upgrades Celldex Therapeutics to Overweight From Equalweight After Barzolvolimab Data	MT
25/09/24	Wells Fargo Upgrades Celldex Therapeutics to Overweight From Equalweight	MT
18/06/24	Stifel Initiates Celldex Therapeutics at Buy Rating With $58 Price Target	MT
11/06/24	Wolfe Research Initiates Coverage on Celldex Therapeutics With Outperform Rating, $51 Price Target	MT
20/12/23	TD Cowen Initiates Celldex Therapeutics at Outperform Rating	MT
10/11/23	Wells Fargo Upgrades Celldex Therapeutics to Equalweight From Underweight With $27 Price Target	MT
06/11/23	HC Wainwright Adjusts Price Target on Celldex Therapeutics to $80 From $73, Maintains Buy Rating	MT
22/08/23	Wells Fargo Starts Celldex Therapeutics With Underweight Rating, $21 Price Target	MT
22/08/23	Analyst recommendations: Applovin, BAE Systems, Evercore, Jefferies, Target...

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	LONZA GROUP AG					+16.67%
	REVOLUTION MEDICINES, INC.					+18.87%
	IQVIA HOLDINGS INC.					+5.13%
	BEONE MEDICINES AG					+17.84%
	CELLTRION, INC.					+39.5%
	MEDPACE HOLDINGS, INC.					-3.13%
	ASCENDIS PHARMA A/S					+27.58%
	EUROFINS SCIENTIFIC SE					+0.23%
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					-3.6%
	Average					+13.23%
	Weighted average by Cap.					+15.69%